157 related articles for article (PubMed ID: 36328922)
1. Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Urol Oncol; 2023 Jan; 41(1):51.e13-51.e23. PubMed ID: 36328922
[TBL] [Abstract][Full Text] [Related]
2. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
3. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma.
Xu X; Zhang S; Wang Y; Zhu Y; Wang J; Guo J
Cancer Med; 2023 May; 12(9):10512-10525. PubMed ID: 37031459
[TBL] [Abstract][Full Text] [Related]
4. Effect of galectin-1 on prognosis and responsiveness of immune checkpoint plus tyrosine kinase inhibition in renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Cancer Med; 2024 Apr; 13(7):e7113. PubMed ID: 38545824
[TBL] [Abstract][Full Text] [Related]
5. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients.
Xu X; Wang Y; Hu X; Zhu Y; Wang J; Guo J
Neoplasia; 2023 Sep; 43():100919. PubMed ID: 37517099
[TBL] [Abstract][Full Text] [Related]
6. Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Cancer Res Treat; 2023 Oct; 55(4):1321-1336. PubMed ID: 37024096
[TBL] [Abstract][Full Text] [Related]
7. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression.
Xu X; Wang Y; Chen Z; Zhu Y; Wang J; Guo J
Immunogenetics; 2023 Apr; 75(2):133-143. PubMed ID: 36515717
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
Scand J Immunol; 2023 Oct; 98(4):e13304. PubMed ID: 37294700
[TBL] [Abstract][Full Text] [Related]
9. SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Xu X; Lin J; Wang J; Wang Y; Zhu Y; Wang J; Guo J
Hum Vaccin Immunother; 2024 Dec; 20(1):2350101. PubMed ID: 38738709
[TBL] [Abstract][Full Text] [Related]
10. Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.
Wang J; Lin J; Wang J; Wang Y; Zhu Y; Xu X; Guo J
Discov Oncol; 2024 Mar; 15(1):86. PubMed ID: 38519766
[TBL] [Abstract][Full Text] [Related]
11. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
13. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H; Omae K; Nemoto Y; Ishiyama R; Tachibana H; Nishimura K; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Int J Clin Oncol; 2024 Apr; 29(4):473-480. PubMed ID: 38345708
[TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Impact of Immune-Related Adverse Events Due to Immune Checkpoint Inhibitor Dual Combination Therapy and Immune Checkpoint Inhibitor Plus Tyrosine Kinase Inhibitor Combination Therapy in Patients with Advanced Renal Cell Carcinoma.
Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
Target Oncol; 2023 Jan; 18(1):159-168. PubMed ID: 36571708
[TBL] [Abstract][Full Text] [Related]
16. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
Bolek H; Yekedüz E; Ürün Y
Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Chablani PV; Karrison T; Stadler WM
Clin Genitourin Cancer; 2022 Dec; 20(6):510-514. PubMed ID: 35869002
[TBL] [Abstract][Full Text] [Related]
18. Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.
Dawsey SJ; Ornstein MC
Curr Oncol; 2021 Nov; 28(6):5019-5024. PubMed ID: 34940060
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
[TBL] [Abstract][Full Text] [Related]
20. Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.
Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Massari F
Future Oncol; 2022 Feb; 18(5):625-634. PubMed ID: 34927453
[No Abstract] [Full Text] [Related]
[Next] [New Search]